Market
Percentage of weight loss in amycretin's phase 3 trial results?
2
Resolution / Starting Odds
Less than 15% • 25%
15% to 20% • 25%
20% to 25% • 25%
More than 25% • 25%
Novo Nordisk's official press releases or published phase 3 trial results
Story
Novo Nordisk's Amycretin Achieves 22% Weight Loss in Early Trial, Shares Jump 11%
Jan 24, 2025, 11:05 AM
Novo Nordisk announced positive results from an early-stage clinical trial of its next-generation experimental obesity drug, amycretin. In the phase 1b/2a trial involving 125 participants with overweight or obesity, those treated with amycretin achieved up to 22% weight loss after 36 weeks. Amycretin is a novel GLP-1 and amylin receptor agonist designed for once-weekly subcutaneous injection. Following the announcement, Novo Nordisk's shares surged by as much as 11%, the most in a month.
View original story
Similar markets
25% to 29.9% • 25%
30% or more • 25%
Less than 20% • 25%
20% to 24.9% • 25%
Trial halted • 25%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
Diarrhea • 25%
Headache • 25%
Nausea • 25%
Vomiting • 25%
More than 24% weight loss • 25%
22% to 24% weight loss • 25%
20% to 22% weight loss • 25%
Less than 20% weight loss • 25%
More than 50% • 25%
Less than 30% • 25%
30% to 40% • 25%
41% to 50% • 25%
15% to 20% • 25%
Less than 15% • 25%
More than 25% • 25%
20% to 25% • 25%
